Search results for "Protease"

showing 10 items of 463 documents

Liver cirrhosis associated with heterozygous alpha-1-antitrypsin deficiency type Pi MS and autoimmune features.

1995

Patients with homozygous protease inhibitor (Pi) type ZZ or a few rare M-like types may develop liver cirrhosis due to intracellular storage of alpha-antitrypsin (AAT), whereas some patients with heterozygous Pi MZ or SZ normally present with transient abnormal liver function tests in childhood. We report a 42-year-old obese patient who developed liver cirrhosis in association with heterozygous Pi MS (AAT) deficiency. Immunohistological and electron microscope examination showed storage of AAT in the hepatocytes. Interestingly, autoimmune features in this patient suggest that abnormal immune responses may contribute to the pathology of chronic liver disease.

AdultLiver CirrhosisMalecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHeterozygoteCirrhosisT-LymphocytesAlpha (ethology)medicine.disease_causeAutoimmunityAutoimmune DiseasesImmunoenzyme TechniquesInternal medicinealpha 1-Antitrypsin DeficiencyPiMedicineHumansProtease inhibitor (pharmacology)ObesityAutoimmune diseaseAlpha 1-antitrypsin deficiencybusiness.industryGastroenterologymedicine.diseaseTrypsin deficiencyFlow CytometryAlcoholismMicroscopy ElectronEndocrinologyPhenotypeLiveralpha 1-AntitrypsinCytokinesbusinessDigestion
researchProduct

High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression

2013

Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease-activated receptor- 2 (PAR-2) activation by MC-tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR-2 and to examine the relationship between PAR-2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of MC-tryptase,…

AdultMaleCytoplasmPathologymedicine.medical_specialtySodium-Hydrogen ExchangersColorectal cancerLymphovascular invasionSettore MED/06 - Oncologia MedicainvasivenesstryptasePAR-2Cell CountTryptaseModels BiologicalImmunophenotypingNHERF1Intestinal mucosamedicineHumansReceptor PAR-2Mast CellsIntestinal Mucosaprognostic factorProtease-activated receptor 2AgedAged 80 and overbiologyColorectal cancer PAR-2 mast cell tryptase NHERF1 prognostic factor invasiveness aggressivenessOriginal ArticlesCell BiologyaggressivenessMiddle AgedPhosphoproteinsPrognosismedicine.diseaseMast cellColorectal cancermedicine.anatomical_structurebiology.proteinMolecular MedicineImmunohistochemistryFemaleTryptasesmast cellColorectal Neoplasms
researchProduct

Inhibition of neuropeptide degradation suppresses sweating but increases the area of the axon reflex flare.

2013

The neuropeptides CGRP (calcitonin gene-elated peptide) and substance P (SP) mediate neurogenic inflammation. Both are degraded by the neutral endopeptidase (NEP) which can be blocked by phosphoramidon. The aim was to evaluate the effect of NEP inhibition on sweating and vasodilatation. Dermal microdialysis was performed on the skin of 39 subjects. Two fibres were perfused with phosphoramidon (0.01%, 0.02% or 0.2%), two with saline. Acetylcholine (ACh) was either added to the microdialysis perfusate (n = 30, 10(-2)  m) or thermoregulatory sweating was induced (n = 9). Co-application of phosphoramidon reduced cholinergic and thermoregulatory sweating. However, the flare size - a localized in…

AdultMaleMicrodialysismedicine.medical_specialtyCalcitonin Gene-Related PeptideNeuropeptideSubstance PSweatingDermatologyCalcitonin gene-related peptideSubstance PBiochemistrychemistry.chemical_compoundInternal medicineReflexmedicineHumansProtease InhibitorsMolecular BiologySkinNeurogenic inflammationintegumentary systemChemistryPhosphoramidonGlycopeptidesrespiratory systemAxonsEndocrinologyCholinergicFemaleNeprilysinAcetylcholinemedicine.drugBody Temperature RegulationExperimental dermatology
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but <1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: A case report

2002

Reversible posterior leukoencephalopathy syndrome (RPLS) is an uncommon entity related to multiple and different pathologies, the most common being hypertensive crisis. It is believed to be secondary to the breakdown on the blood-brain barrier. At the beginning, it is undistinguishable from other leukoencephalopathies. However, the disappearance of brain lesions after removal of the potential cause, establish the differential diagnosis with other leukoencephalopathies. We present the case of an HIV-infected patient with a RPLS related to a hypertensive crisis short after the initiation of indinavir-containing highly active antiretroviral therapy. Once blood pressure was controlled and indin…

AdultMalePathologymedicine.medical_specialtyHypertensive encephalopathymedicine.medical_treatmentHIV InfectionsIndinavirIndinavirAntiretroviral Therapy Highly ActiveHypertensive EncephalopathyInternal MedicinemedicineHumansChemotherapymedicine.diagnostic_testbusiness.industryProgressive multifocal leukoencephalopathyvirus diseasesMagnetic resonance imagingHIV Protease Inhibitorsmedicine.diseaseMagnetic Resonance ImagingHyperintensityNelfinavirDifferential diagnosisbusinessmedicine.drugAmerican Journal of Hypertension
researchProduct

Reduction of plasma granzyme A correlates with severity of sepsis in burn patients.

2009

The risk of mortality is high in burn patients and correlates with age, burn area extent, and sepsis. Immunosuppression has been reported to occur after severe burn. Cytotoxic cells possess specialized granules containing perforin and a group of serine proteases (granzymes). Granzyme A is a serine protease constitutively expressed by gammadelta and NK cells, in agreement with their functional cytolytic potential. In vitro studies have shown that GrA may be released extracellularly during cytotoxic cell degranulation, indicating the activation of cytotoxic cells. The aim of our study was to determine plasma GrA activity in burned patients and to verify if decreased GrA levels were associated…

AdultMaleProteasesCritical Care and Intensive Care MedicineGranzymesNatural killer cellSepsisSepsisparasitic diseasesmedicineCytotoxic T cellHumansAgedRetrospective Studiesbiologybusiness.industryDegranulationGeneral MedicineMiddle Agedmedicine.diseasePrognosisAnti-Bacterial Agentsmedicine.anatomical_structurePerforinGranzymeImmunologyEmergency Medicinebiology.proteinGranzyme ASurgeryFemalebusinessBurnsBiomarkersBurns : journal of the International Society for Burn Injuries
researchProduct

Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease

1988

In a six-month multicenter feasibility and safety study, 20 patients, who all had a congenital deficiency of alpha-1-protease inhibitor (A1PI) of the PiZ phenotype accompanied by a chronic obstructive lung disease, were treated with human-plasma-derived A1PI. A weekly dose of 60 mg/kg, administered intravenously, was shown to be sufficient to maintain patient serum levels above the threshold limit of 35 percent, the serum level of healthy persons of the MZ phenotype. This is supposed to be the minimal effective level for protection against the elastolytic attack of the lung and, therefore, satisfies one of the most important criteria of feasibility of long-term replacement therapy. The glob…

AdultMalealpha 1-Antitrypsin DeficiencymedicineHumansLung Diseases ObstructiveInfusions IntravenousAgedRadial immunodiffusionClinical Trials as TopicLungPancreatic Elastasebiologybusiness.industryBlood ProteinsGeneral MedicineMiddle AgedOuchterlony double immunodiffusionTrypsinmedicine.diseaseAlpha-1 Protease Inhibitor DeficiencyObstructive lung diseasePhenotypemedicine.anatomical_structureImmunologybiology.proteinFemaleAntibodyLung Volume MeasurementsbusinessNephelometrymedicine.drugThe American Journal of Medicine
researchProduct

Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors

2015

Abstract Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians’ choices in hepatitis C therapy and social (macro-) allocation decision-making. The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients shoul…

AdultMalehepatitis C virusmedicine.medical_specialtyPathologyCost-Benefit AnalysisHepatitis C virusDecision MakingProtease InhibitoreducationAlternative medicineHepacivirusDirect-acting antiviralmedicine.disease_causeAntiviral AgentsSettore MED/02 - Storia Della MedicinaResource (project management)medicineHumansProtease InhibitorsEthics MedicalEthichealth technology assessmentCost-Benefit AnalysiDeferralIntensive care medicineEthical frameworkdirect-acting antiviralsAgedAntiviral AgentSettore MED/12 - GastroenterologiaHepaciviruHepatologybusiness.industryGastroenterologyHealth technologyHepatitis CMiddle AgedSettore MED/43 - MEDICINA LEGALEmedicine.diseaseHepatitis CethicsFirst generationDrug Therapy CombinationFemaleHepatitis C virubusinessHuman
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

Role of proinflammatory alleles in longevity and atherosclerosis: results of studies performed on -1562C/T MMP-9 in centenarians and myocardial infar…

2007

Centenarians are characterized by marked delay or escape from age-associated diseases that cause mortality at earlier ages. Jointly, atherosclerosis and its complications, such as myocardial infarction (AMI), significantly contribute to mortality in the elderly. Inflammation is a key component of atherosclerosis and inflammatory genes are good candidates for the risk of the development of atherosclerosis. Genetic traits contribute to the risk of AMI and allelic variations in inflammatory genes should boost the risk of disease. If proinflammatory genotypes significantly contribute to the risk of AMI, alleles associated with disease susceptibility should not be included in the genetic backgro…

AdultMalemedia_common.quotation_subjectLongevityMyocardial InfarctionInfarctionInflammationSingle-nucleotide polymorphismDiseaseCoronary Artery DiseaseBiologyPolymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineCohort StudiesMetalloproteaseHistory and Philosophy of ScienceGene FrequencymedicineSNPHumansAllelePolymorphismSicilyAllelesmedia_commonAged 80 and overInflammationGeneral NeuroscienceLongevityMiddle Agedmedicine.diseaseMatrix Metalloproteinase 9InfarctionImmunologyFemalemedicine.symptomAnnals of the New York Academy of Sciences
researchProduct